Latest News

Created in 2017, the STROK@LLIANCE brand has quickly built a reputation for quality and success in the field of preclinical services in neurology.It is a real pleasure for us to see our brand building value.Having already secured trademark protection in Europe, ETAP-Lab is proud to announce that the Japanese patent office has now approved our application to register the STROK@LLIANCE trademark.We decided to include an image of the official document because, in addition to its legal value, it is beautifully

ETAP-Lab was honoured to be among Nexira’s guests last week at the Printemps Haussmann Coupole in Paris, attending the launch party for its new inavea™ range - the first sustainable, organic ingredients brand with distinctive and proven health benefits. Starting in 2020 with inavea pure acacia, an all-natural dietary fiber sourced from carefully selected acacia trees, Nexira offers a high digestive tolerance and a prebiotic effect. Preclinical studies conducted by ETAP-Lab have proven the health benefits of other products on offer from

ETAP-Lab will participate at MEDICA next 19 November in Dusseldorf. Our experts Dr. Jean-François BISSON (VP) and Dr. Nicolas Violle (CEO) will present ETAP-Lab’s services in the fields of preclinical Dermatology with our partner CYCERON.ETAP-Lab has a track-record of success in the testing of medical devices in the field of Dermatology, such as dressing, plaster and bandage.Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you. Contact us

ETAP-Lab will participate at Bio Europe next 11-13 November in Hamburg. Our experts Dr. Jean-François BISSON (VP) and Dr. Nicolas Violle (CEO) will present ETAP-Lab’s services in the fields of preclinical Dermatology and Central Nervous System. Please feel free to contact us if you want to schedule a one-to-one meeting. Looking forward to meeting with you.

Last June, we produced the 1st batch of beta-amyloid1-42 oligomers in our new facilities, using our unique know-how for oligomers production and stabilization (see here). We are very happy and proud to announce that we have now extensively validated the following in vitro pharmacological models: A model of Alzheimer’s disease: challenge with beta-Amyloid1-42 oligomers in rat primary cortical neuron culture; A model of Parkinson’s disease: challenge with alpha-synuclein oligomers in rat primary cortical neuron culture. Batch-to-batch oligomer production reproducibility has been controlled, confirming the

ETAP-Lab is seeking for a laboratory technician for its STROK@LLIANCE in vivo lab in Caen (14000). Job: laboratory technician Type of contract: temporary position (CDD) Duration: 6 months (potentially extended) Under the supervision of the project manager you will contribute to the set up and performing of in vivo and in vitro experimentations and you will ensure proper lab functioning; both in compliance with the Good Laboratory Practice. You have now the opportunity to join a young and dynamic team looking for challenge in a

ETAP-Lab had an instrumental position in Ingredia's projects and successfully predicted in mice the efficacy of Pep2Dia, a new bioactive ingredient expected to reduce postprandial blood sugar levels. Ingredia presented at Vitafoods (2019, 8th May 2019, Geneva) clinical evidence that Pep2Dia decreases postprandial blood sugar levels in a prediabetic population. The clinical studies were performed after ETAP-Lab showed a significant benefit of Pep2Dia. Indeed, when administered 15 minutes before a sugar shot in db/db

ETAP-Lab launches a new in vitro pharmacology activity in the field of proteopathic neurodegenerative diseases ETAP-Lab proudly announces the launch of ETAP-Cell: a new in vitro pharmacology activity in the field of proteopathic neurodegenerative diseases. The creation of this activity has been made possible by the recruitment of Dr Ahmad Allouche (former Head of Biology at SynAging) who is placing his unique expertise in the solubilization and stabilization of oligomeric proteins (AβO, αSO and TauO) at the disposal of ETAP-Lab. As

 This year was very exciting for ETAP-Lab and we would like to share with you some of the 2018 major achievements:A new atopic dermatitis model, the DNCB-induced model in Balb/c mice, has been developed with effective studies already in progress.New studies for the account of TEMESIS have been performed showing remarkable effects of their lead TEM1657 drug candidate on Psoriasis and results have been presented in different congresses. Different formulations of their product remaining to be characterized.Jean-François Bisson participated to